US 12226403
Tebipenem pivoxil immediate and modified release oral dosage forms
granted A61KA61K31/427A61K9/0053
Quick answer
US patent 12226403 (Tebipenem pivoxil immediate and modified release oral dosage forms) held by SPERO THERAPEUTICS, INC. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- SPERO THERAPEUTICS, INC.
- Grant date
- Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/427, A61K9/0053, A61K9/2013, A61K9/2018